Nizatidine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
update infobox, refs, links, portals
templated cites
Line 61: Line 61:


<!-- Society and culture -->
<!-- Society and culture -->
It was patented in 1980 and approved for medical use in 1988.<ref name="FDA approval">{{cite web | title=Nizatidine: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019508 | access-date=20 March 2020}}</ref><ref>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=44 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444 |language=en}}</ref> It was developed by [[Eli Lilly and Company|Eli Lilly]]. Brand names include '''Tazac''' and '''Axid'''.
It was patented in 1980 and approved for medical use in 1988.<ref name="FDA approval">{{cite web | title=Nizatidine: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019508 | access-date=20 March 2020}}</ref><ref>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin | name-list-format = vanc |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=44 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444 |language=en}}</ref> It was developed by [[Eli Lilly and Company|Eli Lilly]]. Brand names include '''Tazac''' and '''Axid'''.


==Medical use==
==Medical use==
Line 71: Line 71:


==History and development==
==History and development==
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1988.<ref name="FDA approval" /> It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]].<ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 ] {{webarchive |url=https://web.archive.org/web/20080526223021/http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 |date=May 26, 2008 }}</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm] {{webarchive |url=https://web.archive.org/web/20131226093839/http://www.reliantrx.com/investor/press_releases/072604.htm |date=December 26, 2013 }}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>{{cite web|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 |title=United States Patent: 6930119 |publisher=Patft.uspto.gov |date= |accessdate=2015-10-11}}</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm] {{webarchive |url=https://web.archive.org/web/20070814071007/http://www.reliantrx.com/investor/press_releases/063005.htm |date=August 14, 2007 }}</ref>
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1988.<ref name="FDA approval" /> It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]].<ref name="encyclopedia">{{cite web | title = Eli Lilly and Company and Reliant Pharmaceuticals Announce Agreement for U.S. Sales and Marketing Rights to Axid(R) | date = 7 September 2000 | url = http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 | archive-url = https://web.archive.org/web/20080526223021/http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 | archive-date=May 26, 2008 | work = High Beam Encyclopedia }}</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref name="reliant2004">{{cite web | title = Reliant Pharmaceuticals to Launch AxidŽ Oral Solution | url = http://www.reliantrx.com/investor/press_releases/072604.htm | archive-url = http://www.reliantrx.com/investor/press_releases/072604.htm | archive-date=30 October 2005 | date = 26 July 2004 | publisher = Reliant Pharmaceuticals, LLC }}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>{{cite patent | country = US | number = 6930119 | title = Liquid pharmaceutical composition | inventor = Bobotas G, Fawzy AA | assign1 = Reliant Pharmaceuticals, LLC | gdate = 24 June 2005 }}</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">{{cite web | title = Reliant Pharmaceuticals Announces the Sale of Axid® Oral Solution to Braintree Laboratories | url = http://www.reliantrx.com/investor/press_releases/063005.htm | archive-url = https://web.archive.org/web/20070814071007/http://www.reliantrx.com/investor/press_releases/063005.htm | archive-date=August 14, 2007 | publisher = Reliant Pharmaceuticals, LLC }}</ref>


Nizatidine proved to be the last new histamine H<sub>2</sub> receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.{{citation needed|date=January 2016}}
Nizatidine proved to be the last new histamine H<sub>2</sub> receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.{{citation needed|date=January 2016}}


==See also==
== See also ==
* [[Famotidine]] (Pepcid) — another popular H<sub>2</sub> receptor antagonist
* [[Famotidine]] (Pepcid) — another popular H<sub>2</sub> receptor antagonist


==References==
== References ==
{{Reflist}}
{{Reflist}}


==External links==
== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/nizatidine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Nizatidine }}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/nizatidine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Nizatidine }}


Revision as of 09:16, 22 March 2020

Nizatidine
Clinical data
Trade namesAxid, Tazac
AHFS/Drugs.comMonograph
MedlinePlusa694030
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: OTC / Rx-only
Pharmacokinetic data
Bioavailability>70%
Protein binding35%
MetabolismLiver
Elimination half-life1–2 hours
ExcretionKidney
Identifiers
  • (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.155.683 Edit this at Wikidata
Chemical and physical data
FormulaC12H21N5O2S2
Molar mass331.46 g/mol g·mol−1
3D model (JSmol)
  • [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C
  • InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ checkY
  • Key:SGXXNSQHWDMGGP-IZZDOVSWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

It was patented in 1980 and approved for medical use in 1988.[1][2] It was developed by Eli Lilly. Brand names include Tazac and Axid.

Medical use

Main article: H2 antagonist

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[3]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[3]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1988.[1] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[4] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[5] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[6] protecting the product) to Braintree Laboratories.[7]

Nizatidine proved to be the last new histamine H2 receptor antagonist introduced prior to the advent of proton pump inhibitors.[citation needed]

See also

  • Famotidine (Pepcid) — another popular H2 receptor antagonist

References

  1. ^ a b "Nizatidine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 20 March 2020.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN 9783527607495. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  3. ^ a b "Nizatidine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 25 January 2018. PMID 31643707. NBK548387. Retrieved 19 March 2020. {{cite book}}: Cite has empty unknown parameter: |1= (help)
  4. ^ "Eli Lilly and Company and Reliant Pharmaceuticals Announce Agreement for U.S. Sales and Marketing Rights to Axid(R)". High Beam Encyclopedia. 7 September 2000. Archived from the original on May 26, 2008.
  5. ^ "Reliant Pharmaceuticals to Launch AxidŽ Oral Solution". Reliant Pharmaceuticals, LLC. 26 July 2004. {{cite web}}: Check |archive-url= value (help)
  6. ^ US 6930119, Bobotas G, Fawzy AA, "Liquid pharmaceutical composition", issued 24 June 2005, assigned to Reliant Pharmaceuticals, LLC 
  7. ^ "Reliant Pharmaceuticals Announces the Sale of Axid® Oral Solution to Braintree Laboratories". Reliant Pharmaceuticals, LLC. Archived from the original on August 14, 2007.

External links

  • "Nizatidine". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nizatidine&oldid=946771773"